Regulatory Benefit-Cost Analysis Under the Trump Administration
President Trump’s deregulatory push will strain benefit-cost analysis.
Promoting Best Practices for U.S. Regulatory Analysis
Benefit-cost analysis experts advocate changes to a draft update of OMB Circular A-4.
COVID-19 and Uncertainties in the Value Per Statistical Life
Uncertainties in value per statistical life estimates impact the extent to which COVID-19 policies yield net benefits.
Regulating Cost-Benefit Analysis
EPA’s advance notice raises fundamental questions about how the agency should weigh costs and benefits.
Regulatory Analysis Under the Trump Administration
Deregulatory executive orders require a new approach to analyzing regulatory impact.
Are We Making Progress in Valuing Health and Longevity in Regulatory Analysis?
Although agencies have made strides concerning values for mortality risk reductions, more research is needed on these values.
New Recommendations for Valuing Mortality Risk Reductions
EPA’s Science Advisory Board offers recommendations to improve cost-benefit analysis.